title: Science to practice: what do molecular biologic studies in rodent models add to our understanding of interventional oncologic procedures including percutaneous ablation by using glyceraldehyde-3-phosphate dehydrogenase antagonists?
abstract: In this basic research study, Ganapathy-Kanniappan et al advance our understanding of how to block the glycolytic pathway to inhibit tumor progression by using image guided procedures (1). This was accomplished by demonstrating their ability to perform molecular targeting of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in human hepatocellular carcinoma (HCC) by using percutaneous injection of either inhibitor--3-bromopyruvate (3-BrPA) or short hairpin RNA (shRNA). They take the critical step of providing further rationale for potentially advancing this therapy into clinical trials by demonstrating that GAPDH expression strongly correlates with c-jun, a proto-oncogene involved in liver tumorigenesis in human HCC (2).
authors.affiliation: Image-guided Therapy and Interventional Oncology Unit, Department of Radiology Hadassah Hebrew University Medical Center, Jerusalem, Israel. sgoldber@bidmc.harvard.edu
authors.forename: S Nahum
authors.initials: SN
authors.lastname: Goldberg
mesh_terms: D000818:Animals; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000201:enzymology*; D004195:Disease Models, Animal; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases / Q000037:antagonists & inhibitors*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000201:enzymology*; D000090063:Proto-Oncogene Mas; D011773:Pyruvates / Q000494:pharmacology*; D034741:RNA, Small Interfering / Q000494:pharmacology*
chemical_list: C000715470:MAS1 protein, human; D000090063:Proto-Oncogene Mas; D011773:Pyruvates; D034741:RNA, Small Interfering; C017092:bromopyruvate; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases